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OBJECTIVE — We evaluated the role of fatty liver in the alteration of insulin sensitivity and
-cell function in two groups of obese adolescents, differing in hepatic fat content (hepatic fat
fraction [HFF]) but with similar intrabdominal intramyocellular lipid content (IMCL) and over-
all degree of obesity.
RESEARCH DESIGN AND METHODS — We studied 23 obese adolescents with high
HFF (HFF 5.5%) and 20 obese adolescents with low HFF (HFF 5.5%), matched for age,
Tanner stage, BMI z score, and percentages of body fat, visceral fat, and IMCL. All subjects
underwent an oral glucose tolerance test and a two-step hyperinsulinemic-euglycemic clamp,
magnetic resonance imaging and
1H nuclear magnetic resonance to assess abdominal fat distri-
bution, HFF, and IMCL, respectively.
RESULTS — The high HFF group showed signiﬁcantly lower whole-body insulin sensitivity
index (P  0.001) and estimates of insulin secretion (P  0.03). The baseline hepatic glucose
production (EGP) rate was not different between the two groups. Suppression of EGP was
signiﬁcantly lower (P  0.04) in the high HFF group during low-dose insulin; no differences
were observed during the second step. Baseline fatty acids, glycerol concentrations, and clamp
suppression of glycerol turnover did not differ between the groups. During the second step, the
glucose disposal rate was signiﬁcantly lower (P  0.01) in the high HFF group.
CONCLUSIONS — Fatty liver, independent of visceral fat and IMCL, plays a central role in
the insulin-resistant state in obese adolescents.
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F
at accumulation in the liver is be-
coming a common complication in
pediatricobesityandisstronglyas-
sociated with alterations in glucose and
lipid metabolism, possibly because of
the presence of insulin resistance (1).
The mechanisms responsible for the in-
terrelationships between fatty liver dis-
ease and insulin resistance are not
clearly understood; in fact, it remains
unclear whether hepatic steatosis is a
consequence or a cause of derange-
ments in insulin sensitivity. As recently
shownbyourgroup,theseverityoffatty
liver, independent of obesity, is associ-
ated with the presence of pre-diabetes
(2).Ofnoteisthefactthatinthosestud-
ies, fatty liver accumulation rose in par-
allel with increasing visceral fat as well
as intramyocellular fat (intramyocellu-
lar lipid content [IMCL]) (2,3). There-
fore, from those earlier studies it was
virtually impossible to assess the inde-
pendent contribution of the liver to the
development of insulin resistance, be-
cause both visceral fat and intramyocel-
lular fat are also known to modulate
insulin sensitivity (4,5).
Thus, herein we examined the exclu-
sive role of fatty liver in the alteration of
insulin sensitivity and -cell function in
twogroupsofobeseadolescents,differing
in the amount of hepatic fat content (he-
patic fat fraction [HFF]), but character-
ized by similar distribution of abdominal
and muscle fat and overall degree of obe-
sity. We hypothesized that, independent
of visceral fat and IMCL, liver fat content
would be a key determinant of global in-
sulin resistance, involving liver, muscle,
and adipose tissue.
RESEARCH DESIGN AND
METHODS— Sixty-one adolescents,
with a BMI z score ranging from 2.2 to
2.5, recruited from the Pediatric Obesity
Clinic at Yale participated in the present
metabolic and imaging study (Table 1).
They were not taking any medications
knowntoaffectliverfunctionoralterglu-
cose or lipid metabolism. Information on
alcohol consumption was obtained for all
subjects using a questionnaire. All partic-
ipants had a detailed medical history, a
complete physical examination, includ-
ing assessment of Tanner stage of devel-
opment, and a standard oral glucose
tolerance test (OGTT) (6), and they all
underwent detailed phenotyping of vis-
ceral and liver fat by magnetic resonance
imaging(MRI)andofIMCLby
1Hnuclear
magnetic resonance (NMR). Based on the
analysis of hepatic fat content, subjects
weredividedintotwogroups:ahighliver
fat content group (HFF 5.5%) consist-
ingof23obeseadolescentsandalowliver
fat content group (HFF 5.5%) consist-
ing of 38 obese adolescents. To fulﬁll the
aim of the study, we selected 20 patients
fromthelowliverfatcontentgroupshow-
ing a distribution of visceral and muscle
fat similar to that of the high liver fat con-
tent group (visceral fat ranged from 33 to
90 cm
2 and IMCL ranged from 0.3 to
1.9% water). Therefore, the study cohort
was the following: 23 subjects (11 male
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Americans, and 10 Hispanics) in the high
liver fat content group and 20 subjects (8
male and 12 female; 6 Caucasians, 8 Afri-
can Americans, and 6 Hispanics) in the
low liver fat content group. The two
groups had different hepatic fat content
but similar visceral fat and IMCL (Table
1). Before the formation of the two
groups, we were unaware of potential dif-
ferences in any of the outcomes mea-
sured. Thirty percent of the subjects were
reported on previously (2).
The study protocol was approved by
theinstitutionalreviewboardofYaleUni-
versity School of Medicine. Written pa-
rental consent and child assent were
obtained before the study.
Metabolic studies
OGTT and estimates of insulin sensi-
tivity and -cell function. Subjects
were studied at the Yale Clinical Center
Investigation at 8:00 A.M., after a 10-h
overnight fast. All had an OGTT (7).
Estimates of insulin sensitivity were
calculated using homeostasis model as-
sessment of insulin resistance (HOMA-
IR),deﬁnedbyfastinginsulin(microunits
per milliliter)  fasting glucose (milli-
grams per deciliter) (7) and whole-body
insulin sensitivity index (WBISI), based
onmeanvaluesofinsulin(microunitsper
milliliter)andglucose(milligramsperde-
ciliter) obtained from the OGTT and the
corresponding fasting values (7). The in-
sulinogenicindex(IGI),whichrepresents
early-phase insulin secretion, was calcu-
lated as IGI insulin (0–30 min) in
microunits per milliliter divided by the 
glucose (0–30 min) in milligrams per de-
ciliter (8). The disposition index (DI) was
calculated as the product of the IGI and
the WBISI, based on the curvilinear rela-
tion of these OGTT-derived variables, as
described by our group in obese children
and adolescents (8).
Areas under the curve (AUC) of insulin
and glucose were calculated by the trape-
zium rule (9). Overall glucose-stimulated
insulin secretion was calculated as the
incremental AUC ratio ( AUCinsulin/
 AUCglucose) (10).
Hyperinsulinemic-euglycemic clamp.
After an overnight fast, at 7:00 A.M., two
intravenous catheters, one for blood sam-
pling and one for infusion of glucose, in-
sulin, and tracers, were inserted in the
antecubital vein of each arm after local
lidocaine inﬁltration. The sampling arm
was kept in a heated box for arterializa-
tion of blood. Whole-body insulin sensi-
tivity was measured by two-step
euglycemicclamp,byinfusinginsulinasa
primed continuous infusion at 4 and 80
mU m
2 min
1.Eachsteplasted2h.A
primed continuous infusion of 6,6-
deuterium glucose and of
2H5-glycerol
wereusedtoquantifytheeffectsofinsulin
on glucose and glycerol turnover. To
maintain the plasma enrichment of
2D-
glucose constant at baseline value
throughout the clamp, we used the Hot
GINFmethod,aspreviouslyreported(5).
Arterialized blood samples were collected
every10minduringthelast30minofthe
baseline period and during each step of
the clamp for measurement of glucose
andglycerolenrichments,hormones,and
substrates.
Imaging studies
Abdominal MRI and total body compo-
sition (dual-energy X-ray absorptiom-
etry). Multislice abdominal MRI studies
were performed on a Siemens Sonata 1.5
T system (11). Total body composition
was measured by dual-energy X-ray ab-
sorptiometry with a Hologic scanner
(Hologic, Boston, MA).
1H-NMR spectroscopy: IMCL measure-
ment. Localized
1H NMR spectra of the
soleus muscle were acquired on a 4T Bio-
spec system (Bruker Instruments, Bil-
lerica, MA) (12).
Fast-MRI: liver fat content. Liver fat
content(hepaticfatfraction[%HFF])was
measured by MRI using the two-point
Dixon method as modiﬁed by Fishbein et
al. (13) and reported by Cali et al. (2).
Analytical procedures and calcula-
tions. Plasma glucose was determined
with a YSI 2700 analyzer and plasma free
fatty acids were determined by a colori-
metricmethod.Plasmainsulin,adiponec-
tin, and leptin levels were measured with
a radioimmunoassay (Linco, St. Charles,
MO) and plasma C-peptide levels were
measured using a kit (Diagnostic Prod-
ucts,LosAngeles,CA).Analysisofenrich-
ments of
2D-glucose and
2H5-glycerol in
plasma was done as described elsewhere
(5).
Theglucoseinfusionrateswerecalcu-
latedduringthelast30minofeachstepof
the clamp. Endogenous (mainly hepatic)
glucose production (EGP) and glycerol
turnover at baseline and during the two
steps of the insulin clamp, along with the
clamped glucose disposal rates, were cal-
culated as reported previously (5). The
percent suppression of EGP and glyc-
erol turnover during low- and the high-
dose insulin were used as indexes of the
sensitivity of EGP and peripheral lipol-
ysis to insulin. The percent suppression
Table 1—Clinical characteristics of the study cohort
High liver fat
content
Low liver fat
content P value
n 23 20
Race (C/AA/H) 10/3/10 6/8/6 0.1
Sex (male 19/female 24) 11/12 8/12 0.6
Tanner stage (II/III/IV) 4/10/9 2/11/7 0.7
NGT/IGT 6/17 8/12 0.3
Age (years) 13.8  0.52 13.4  0.54 0.5
BMI (kg/m
2) 35.5  1.19 35.7  1.87 0.9
BMI z score 2.33  0.06 2.25  0.09 0.8
Surface area (m
2) 1.92  0.05 1.96  0.07 0.6
Fat mass (kg) 35.6  1.78 38.9  3.16 0.4
Lean body mass (kg) 50.4  2.26 53.9  2.56 0.4
Body fat (%) 40.5  1.20 39.9  1.19 0.6
Body fat distribution
Abdominal
Visceral fat (cm
2) 65.3  3.7 61.1  5.81 0.4
Subcutaneous fat (cm
2) 514.3  30.8 545.4  54.4 0.6
Liver
HFF (%) 17.1  2.37 1.11  0.34 0.0001
Muscle
EMCL (% water) 1.68  0.50 1.86  0.44 0.5
IMCL (% water) 1.17  0.11 0.93  0.11 0.2
Data are n or means  SEM. AA, African American; C, Caucasian; EMCL, extramyocellular lipid content; H,
Hispanic; IGT, impaired glucose tolerance; NGT, normal glucose tolerance.
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of the insulin clamp was used as index
of the degree of endogenous insulin
secretion.
Insulinclearanceduringthetwosteps
of the clamp was calculated by dividing
the rate of insulin infusion by the mean
steady-state insulin level during the insu-
lin infusion (14). In addition, to correct
insulin clearance for the contribution of
the residual endogenous insulin secre-
tion, we also calculated the metabolic
clearance rate of insulin, taking into ac-
counttheconcentrationsofC-peptidebe-
fore and at the end of each step of the
clamp, as reported by Ferrannini et al.
(15).
Statistical analyses
To test group differences in clinical and
metabolic variables we used the Mann-
Whitney U test. Differences in sex and
race prevalence between groups were as-
sessed by 	
2 test. Correlations were as-
sessed by Spearman rank correlation.
Sample size calculations were based
on the ability to detect differences in in-
sulin sensitivity between subjects with
high and low liver fat content. From an
earlier study in obese adolescents, we ob-
servedastandardizeddifferenceof
1.00
(d  1.00) in insulin resistance as mea-
sured by the crude HOMA-IR index (2).
We expected similar differences in our
current study for outcomes derived from
the OGTT and the hyperinsulinemic-
euglycemic clamp. With use of a two-
sided Mann-Whitney U test, group
sample sizes of 23 and 20 achieve 88%
power at 0.05 to detect a standard-
izeddifferenceof1.0(d1.00)ininsulin
sensitivity.
Statistical analyses were performed
with SPSS (16.0 for Windows; SPSS, Chi-
cago, IL). All data are expressed as
means  SEM. P  0.05 was considered
statistically signiﬁcant.
RESULTS
Anthropometric characteristics and
body distribution
The sex, race, age distribution, BMI, BMI
z score, surface area, fat mass, percent
bodyfat,andleanbodymassweresimilar
between the groups. By design, the two
groups were signiﬁcantly discordant for
percentHFF(P0.0001)buthadsimilar
visceral fat and subcutaneous fat
amounts, as well as intramyocellular and
extramyocellular muscle lipid contents
(Table 1).
Estimates of insulin sensitivity and
secretion
Fasting glucose concentrations were sim-
ilar between the two groups; whereas the
2-h glucose levels tended to be higher in
the high liver fat content group. The high
liver fat content group showed signiﬁ-
cantlyhigherlevelsoffastinginsulin(P
0.03)andC-peptidelevelsandatrendfor
higher 2-h insulin concentrations (P 
0.06). The high liver fat content group
had a signiﬁcantly higher level of
HOMA-IR (P  0.002) and lower WBISI
(P  0.001) than the low liver fat content
group (Table 2).
Although the high liver fat content
group showed a trend for a lower ﬁrst-
phase insulin secretion (IGI) (P  0.1), in
agreement with previous reports (10,16)
it was not statistically signiﬁcant. No dif-
ferenceswereobservedintheincremental
AUC ratio. However, when we calculated
the disposition index, it was signiﬁcantly
lower in the high liver fat content group
(P  0.03).
Metabolic characteristics
Fastingleptinconcentrationsweresimilar
in the two groups, reﬂecting their equiv-
alent amounts of adiposity. In contrast,
plasma adiponectin concentrations were
signiﬁcantly lower in the high liver fat
content group (P  0.004) (Table 2). In-
terleukin-6 levels were not signiﬁcantly
different between the groups. Alanine
transaminase and aspartate aminotrans-
ferase values and triglyceride levels were
signiﬁcantly higher in the high liver fat
content group. Both groups had similar
systolic and diastolic blood pressure
values.
Measure of insulin sensitivity during
the clamp
Duringthetwostepsoftheclamp,plasma
glucose concentrations were maintained
atbaselinevalues,andsimilarsteady-state
plasma insulin concentrations were
achievedinbothgroupsduringthelast60
min of each step (ﬁrst step 39.6  3.0 vs.
Table 2—Metabolic characteristics of the study cohort
High liver fat
content
Low liver fat
content P value
n 23 20
Fasting glucose (mg/dl) 96.7  1.90 97.3  2.09 0.8
2-h glucose (mg/dl) 140.6  4.47 128.3  6.95 0.2
Fasting insulin (U/ml) 33.6  2.54 26.6  3.08 0.03
2-h insulin (U/ml) 256.7  32.9 174.5  37.8 0.06
Fasting C-peptide (pmol/ml) 1,271.8  81.3 954.6  76.3 0.01
HOMA-IR (dl   IU
1)/(ml   mg
1) 10.9  1.14 6.48  0.73 0.002
WBISI (dl   ml
1)/(mg   IU
1) 1.0  0.10 1.98  0.27 0.001
IGI (dl   IU
1)/(ml   mg
1) 3.5  0.27 4.6 0.65 0.1
Disposition index 
(dl   ml
1)(ml   mg
1)/

(dl   IU
1)(mg   IU
1) 3.9  0.38 6.2  0.83 0.03
 AUCinsulin/ AUCglucose (dl   IU
1)/
(ml   mg
1) 4.6  0.50 4.8  0.92 0.6
Adiponectin (mg/l) 6.6  0.61 12.5  1.60 0.004
Interleukin-6 2.47  0.39 1.99  0.25 0.8
Leptin (g/l) 33.7  3.05 32.0  3.74 0.6
Lipid proﬁle
Plasma fatty acids (mol/l) 623.5  42.0 553.5  38.1 0.3
Low-dose insulin infusion 436.1  38.8 390.8  35.6 0.4
High-dose insulin infusion 109.6  9.6 97.8  11.6 0.3
Plasma glycerol (mol/l) 89.4  5.29 82.3  4.75 0.4
Total cholesterol (mg/dl) 161.7  7.09 152.5  5.70 0.4
LDL cholesterol (mg/dl) 91.8  6.22 90.5  4.84 0.9
HDL cholesterol (mg/dl) 41.7  1.80 46.3  2.0 0.1
Triglycerides (mg/dl) 116.4  12.3 84.9  8.16 0.05
Liver enzymes (units/l)
Alanine transaminase 30.6  4.41 15.4  1.89 0.0001
Aspartate aminotransferase 24.6  1.34 19.7  1.60 0.008
Systolic blood pressure (mmHg) 119.6  2.65 117.5  2.81 0.4
Diastolic blood pressure (mmHg) 70.9  1.50 68.5  2.44 0.4
Data are n or means  SEM.
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U/ml; second step 205.0 
10.9 vs. 195.5  9.8 U/ml).
Thepercentreductionofendogenous
insulin secretion, assessed by using the
C-peptide levels during the clamp, was
similar between the two groups (low dose
9.8  1.5 vs. 8.5  1.9%; P  0.3; high
dose 27.7  4.3 vs. 27.8  4.2%; P 
0.8) in the high and low liver fat content
groups, respectively).
Insulin clearance was not different
betweenthetwogroups(lowdose0.22
0.08 vs. 0.26  0.02 ml   m
2   min
1,
P0.2;highdose0.800.04vs.0.84
0.05 ml   m
2   min
1, P  0.6; in the
high and low liver fat content groups, re-
spectively). In addition, we did not ﬁnd
anydifferencesinthemetabolicclearance
rate of insulin during either step of the
clamp (low dose: 0.93  0.1 vs. 0.99 
0.14ml m
2 min
1,P0.7;highdose
0.90  0.05 vs. 0.93  0.06 ml   m
2  
min
1, P  0.7; in the high and low liver
fat content groups, respectively).
Liver
BasalEGPratesdidnotdifferbetweenthe
groups (78.1  1.9 vs. 79.5  2.8 mg  
m
2   min
1 in the high and low liver fat
content groups, respectively) despite
higher fasting insulin levels. The low in-
sulin infusion caused a greater suppres-
sion of EGP in the low liver fat content
group (P  0.04); whereas during the
high insulin infusion step suppression of
EGPwasidenticalinbothgroups(Fig.1).
In addition, we found a negative correla-
tion between HFF and the percent sup-
pression of EGP during the low-dose
insulin infusion, which tended to reach
signiﬁcance (r  0.293, P  0.08).
Adipose tissue
Basal free fatty acids (FFAs) were not dif-
ferent between the groups (Table 2), de-
spite higher fasting insulin. Baseline
plasma glycerol concentrations (Table 2)
and basal glycerol turnover (14.9  0.77
vs. 16.2  0.81 mg   m
2   min
1,i nt h e
high and low liver fat content groups, re-
spectively) did not differ between the
groups. In the high liver fat content
group, we observed a trend for a lower
percentage of systemic lipolysis suppres-
sion during the low-dose insulin infusion
(P  0.1), whereas during the high-dose
insulin infusion suppression of lipolysis
was similar in both groups (Fig. 1).
Muscle
During the high-dose insulin infusion,
the peripheral glucose disposal rate was
signiﬁcantly lower (P  0.01) in the high
liver fat content group (Fig. 1); as ex-
pected no differences were seen between
groups at the low insulin dose. In addi-
tion, we found a negative correlation be-
tween percent HFF and peripheral
clamped glucose disposal rate during the
high-dose insulin phase (r  0.37, P 
0.02).
CONCLUSIONS— In the present
study, we found that obese adolescents
with high liver fat content, independent
of visceral fat and IMCL, had 1) impaired
insulin action in the liver and in muscle,
2) early defects in -cell function, as
shown by the low disposition index and
3) low adiponectin levels, and 4) a trend
toward lower suppression of glycerol
turnover during the low insulin dose.
Theseresultssuggestthattheliverhas
acentralroleinthecomplexphenotypeof
the insulin resistance state in obese ado-
lescents with fatty liver, as was also previ-
ously shown by Perseghin et al. (17). The
current study, however, cannot prove
causality. Unlike visceral fat and IMCL,
the accumulation of fat in the liver may
not be just a simple marker of insulin re-
sistance. Previous studies from our group
(3,5) showed that both visceral fat and
IMCL are related to insulin sensitivity in
obese adolescents. However, it should be
noted that in those earlier studies we did
not measure liver fat; therefore, we ig-
nored an important ectopic fat. Further-
more, it is well known that visceral and
intrahepatic fat are related to each other
and that both are linked to the same met-
abolic abnormalities. In fact, in previous
studies we found that alterations in glu-
cose and lipid metabolism were seen with
increases in both hepatic fat and visceral
fat (2,3). Nevertheless, because of the si-
multaneous accumulation of fat in the
liver, visceral depot, and skeletal muscle,
we were unable to differentiate the indi-
vidual effect of each one of these on puta-
tive defects in glucose and lipid
metabolism. The results from this study
do not prove that visceral fat and IMCL
arenotrelatedtoinsulinresistance;rather
they mainly suggest that by accounting
for visceral fat and IMCL, hepatic fat is
more than a simple marker of insulin
resistance.
Results from our study are consistent
withthoseofFabbrinietal.(18),showing
in adult obese subjects that intrahepatic
fat, not visceral fat, is linked with meta-
bolic complications of obesity. We ex-
pand on this theme by showing not only
that the visceral fat may just be a marker
of insulin resistance but also that IMCL
may also be an innocent bystander. In ad-
dition, in our study it should be noted
that the groups had relatively low visceral
content as opposed to the study by Fab-
brini et al. (18), in which the visceral vol-
umewasveryhighinabsoluteterms,thus
making it difﬁcult to ultimately exclude
any inﬂuence of the visceral component
on metabolic complications of obesity.
Furthermore, given the young age of
our subjects and the short duration of
obesity, our results indicate that the in-
Figure 1—Percent suppression of hepatic glucose production and lipolysis and muscle insulin sensitivity in low (f) and high ( ) liver fat content
groups, during the low- and high-dose insulin infusion.
Fatty liver and insulin resistance
1820 DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 care.diabetesjournals.orgvolvement of the liver in the pathogen-
esis of insulin resistance and its
associated sequelae may be occurring
very early.
What causes fat to accumulate exces-
sively in the liver is not entirely clear. In-
ability of the subcutaneous adipose tissue
to store triglycerides (3,19), such as in
lipodistrophy, may be a possible cause
(19). More recently, another mechanism
has been proposed for ectopic fat accu-
mulation, which involves alterations in
the regulation of FFAs from plasma by
CD36, a fatty acid transport protein (18).
The liver plays a central role in the
regulation of glucose, fatty acid, and
amino acid metabolism (20). It is the
main source of hepatic glucose produc-
tion and an important site of fatty acid
disposal and insulin degradation (20).
Most of these important functions have
beenfoundtobeimpairedinthepresence
of fatty liver in adults (18,21). In particu-
lar, the study of Gastaldelli et al. (22)
clearly indicates that increased liver fat is
associated with hepatic insulin resistance
inobeseadultswithandwithoutdiabetes,
whereas excess visceral fat affects primar-
ily gluconeogenesis. Because EGP and li-
polysis are more sensitive to suppression
byinsulinthanstimulationofmuscleglu-
cose uptake, we used a low insulin infu-
sion rate (4 mU   m
2   min
1)t o
accurately quantify interindividual varia-
tions in hepatic insulin sensitivity and li-
polysis. We found in obese adolescents
with fatty liver that alterations in the sen-
sitivity to insulin were clearly involving
both liver and peripheral muscle insulin
sensitivity. Although we were unable to
show signiﬁcant differences in suppres-
sion of lipolysis between the two groups,
the high liver fat content group showed a
lower trend of suppression of lipolysis
and higher trend of FFA concentrations.
However, FFA turnover may not neces-
sarily be a reliable indicator of lipolysis
because FFAs can be reesteriﬁed within
adipose tissue; therefore, the possibility
exists that the higher concentrations of
FFAs are due to reduced reesteriﬁcation
in the high liver fat content group.
In this study, the presence of normal
fasting and insulin-stimulated glycerol
turnover and FFAs in the high liver fat
content group argues against an FFA-
induced insulin resistance and against a
primary role of the adipose tissue. On the
other hand, it should be noted that the
high liver fat content group was less tol-
erant to glucose, suggesting that higher
plasma glucose could push de novo lipo-
genesis and therefore contribute to the
availability of nonsystemic fatty acids.
Asexpected,however,boththeEGP
and lipolysis were suppressed to the
same extent during the high-dose insu-
lin step. In contrast, this high dose was
able to bring out the clear difference be-
tween the two groups in muscle insulin
sensitivity.
Although the results of the present
study are consistent with those reported
by Klein and colleagues (23,24) in obese
adolescents with fatty liver, it should be
noted that the obese adolescents in their
study had a liver fat content much greater
(
26%)thanthoseinourstudy(
15%).
Thus, even at modest levels of hepatic fat
contentwefoundandestablishedaglobal
degree of insulin resistance involving the
liver, muscle, and to some extent adipose
tissue.
Although it was previously reported
in adults that liver fat is associated with
decreased insulin clearance (14,25), in
the present study we were unable to ﬁnd
differences between the two groups. The
reason for the lack of difference is not
clear. Factors that may be implicated are
the degree and duration of steatosis and
sample size.
Our study also provides some evi-
dence regarding -cell function in the
context of fatty liver. Using the disposi-
tion index, an estimate of -cell function
weighted by insulin sensitivity, we found
that it was reduced by 30% in the group
with fatty liver (Fig. 1), suggesting that
the -cells are unable to adequately com-
pensate for the ambient level of insulin
resistance and therefore are very vulnera-
ble, thus increasing susceptibility to type
2diabetes.Ofnote,thesubjectswithfatty
liver had elevated 2-h glucose during the
OGTT, which indicates an imminent pre-
diabetic state.
A few limitations are worth noting
here. First, given the cross-sectional na-
ture of our study we were unable to prove
causality, because it is possible that fatty
liver is a primary factor in insulin resis-
tance or that insulin resistance causes
fatty liver. Second, we do not have a
group of subjects who were matched for
liver fat but differed for visceral fat and
IMCL.
In summary, by accounting for vis-
ceral fat and IMCL, intrahepatic fat accu-
mulation is more than a simple marker of
insulin resistance in obese adolescents,
being associated with impaired insulin
sensitivity at the level of the liver, muscle,
and adipose tissue.
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